Equillium Inc Asset Resilience Ratio
Equillium Inc asset resilience ratio. Equillium Inc (EQ) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Equillium Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Equillium Inc (2017–2025)
Asset resilience ratio of Equillium Inc from 2017 to 2025. This chart shows how Equillium Inc's Asset Resilience Ratio has changed over time. Read Equillium Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Equillium Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see EQ total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Equillium Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Equillium Inc Industry Peers by Asset Resilience Ratio
Compare Equillium Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Equillium Inc Asset Resilience Ratio by Year (2017–2025)
Equillium Inc asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Equillium Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $31.89 Million | -- |
| 2024-12-31 | 17.54% | $4.49 Million | $25.60 Million | -17.39pp |
| 2023-12-31 | 34.93% | $17.65 Million | $50.53 Million | +19.73pp |
| 2022-12-31 | 15.19% | $11.92 Million | $78.42 Million | -20.34pp |
| 2021-12-31 | 35.53% | $30.34 Million | $85.41 Million | -32.57pp |
| 2020-12-31 | 68.11% | $58.18 Million | $85.43 Million | -3.78pp |
| 2019-12-31 | 71.88% | $39.92 Million | $55.54 Million | +16.19pp |
| 2018-12-31 | 55.69% | $37.40 Million | $67.16 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $7.15 Million | -- |
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 fo… Read more